Premium
CD‐sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID‐19)
Author(s) -
Sun Pengfei,
Lu Xiaosheng,
Xu Chao,
Wang Yanjin,
Sun Wenjuan,
Xi Jianing
Publication year - 2020
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25804
Subject(s) - coronavirus , virology , inclusion bodies , betacoronavirus , covid-19 , transmembrane protein , virus , middle east respiratory syndrome coronavirus , middle east respiratory syndrome , angiotensin converting enzyme 2 , biology , receptor , medicine , disease , biochemistry , recombinant dna , gene , infectious disease (medical specialty) , pathology , outbreak
Coronaviruses are common human viruses and include the severe acute respiratory syndrome coronavirus (SARS‐CoV), the middle east respiratory syndrome coronavirus and the SARS‐CoV‐2. Coronaviruses mainly bind to transmembrane receptor proteins on the human cell membrane through spike proteins (S‐proteins), thus releasing the RNA of the virus into the interior of the host cell to cause an infection. In this article, we discuss the mechanism and production of cyclodextrin‐soluble angiotensin‐converting enzyme 2 (CD‐sACE2) inclusion compounds in the treatment of SARS‐CoV‐2 infections by blocking S‐proteins. On the basis of the current research evidence, we believe that CD‐sACE2 inclusion compounds have the potential to treat COVID‐19. We hope that our article can provide a theoretical basis for later experiments.